Vascular access for isolated hepatic perfusion in liver metastases. Place of artificial circulation. Literature review
https://doi.org/10.15829/1560-4071-2023-5393
EDN: YADTSI
Abstract
The use of an artificial circulation and endovascular technologies in the treatment of liver metastases of uveal melanoma is a highly relevant area. Uveal melanoma is a rare cancer from the uveal tract of the eye. The liver is the most common site of metastasis and is affected in 70-90% of cases, being the only site of metastasis in about 50% of cases. Survival ranges from two to three months. This literature review describes the following methods of treatment of liver metastases of uveal melanoma using a heart-lung machine: arterial (arterio-caval), portal (porto-caval), arterio-porto-caval, retrograde arterio-portal. Special attention is paid to the endovascular method of treatment.
Literature sources were searched in the following electronic libraries: elibrary.ru, pubmed.ncbi.nlm.nih.gov, researchgate.net.
About the Authors
V. M. Unguryan
Kostroma Oncological Dispensary
Competing Interests:
Kostroma
Competing Interests:
none
A. N. Kazantsev
Kostroma Oncological Dispensary; E.I. Korolev Kostroma Regional Clinical Hospital; B.V. Petrovsky Russian Scientific Center of Surgery, I.M. Sechenov First Moscow State Medical University
Russian Federation
Competing Interests:
Russian Federation
Kostroma, Moscow
Competing Interests:
none
Y. V. Belov
B.V. Petrovsky Russian Scientific Center of Surgery, I.M. Sechenov First Moscow State Medical University
Russian Federation
Competing Interests:
Russian Federation
Moscow
Competing Interests:
none
References
1. Amaro A, Gangemi R, Piaggio F, et al. The biology of uveal melanoma. Cancer Metastasis Rev. 2017 Mar;36(1):109-140. doi: 10.1007/s10555-017-9663-3. PMID: 28229253; PMCID: PMC5385203.
2. Aronow ME, Topham AK, Singh AD. Uveal Melanoma: 5-Year Update on Incidence, Treatment, and Survival (SEER 1973-2013). Ocul Oncol Pathol. 2018 Apr;4(3):145-151. doi: 10.1159/000480640.
3. Zherko I.Yu., Naumenko L.V., Zhilyaeva E.P., et al. Treatment outcomes in patients with metastatic uveal melanoma: a retrospective monocenter study. Issues of oncology. 2022; 68(2): 224-231. DOI: 10.37469/0507-3758-2022-68-2-224-231
4. Aronow ME, Topham AK, Singh AD. Uveal Melanoma: 5-Year Update on Incidence, Treatment, and Survival (SEER 1973-2013). Ocul Oncol Pathol. 2018 Apr;4(3):145-151. doi: 10.1159/000480640.
5. Ben-Shabat I, Belgrano V, Ny L, et al. Long-Term Follow-Up Evaluation of 68 Patients with Uveal Melanoma Liver Metastases Treated with Isolated Hepatic Perfusion. Ann Surg Oncol. 2016;23(4):1327-34. doi: 10.1245/s10434-015-4982-5.
6. Aronow ME, Topham AK, Singh AD. Uveal Melanoma: 5-Year Update on Incidence, Treatment, and Survival (SEER 1973-2013). Ocul Oncol Pathol. 2018 Apr;4(3):145-151. doi: 10.1159/000480640.
7. Ben-Shabat I., Belgrano V., Hansson C., Olofsson Bagge R. The effect of perfusate buffering on toxicity and response in isolated hepatic perfusion for uveal melanoma liver metastases.Int J Hyperth. 2017; : 1-17
8. Nathan P, Cohen V, Coupland S, et al. Uveal Melanoma UK National Guidelines. Eur J Cancer. 2015 Nov;51(16):2404-12. doi: 10.1016/j.ejca.2015.07.013.
9. Rowcroft A, Loveday BPT, Thomson BNJ, et al. Systematic review of liver directed therapy for uveal melanoma hepatic metastases. HPB (Oxford). 2020;22(4):497-505. doi: 10.1016/j.hpb.2019.11.002.
10. Yang XY, Xie F, Tao R, et al. Treatment of liver metastases from uveal melanoma: a retrospective single-center analysis. Hepatobiliary Pancreat Dis Int. 2013 Dec;12(6):602-6. doi: 10.1016/s1499-3872(13)60095-8.
11. Mariani P, Almubarak MM, Kollen M, et al. Radiofrequency ablation and surgical resection of liver metastases from uveal melanoma. Eur J Surg Oncol. 2016 May;42(5):706-12. doi: 10.1016/j.ejso.2016.02.019.
12. Mariani P, Piperno-Neumann S, Servois V, et al. Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie. Eur J Surg Oncol. 2009 Nov;35(11):1192-7. doi: 10.1016/j.ejso.2009.02.016.
13. Gonsalves CF, Eschelman DJ, Adamo RD, et al. A Prospective Phase II Trial of Radioembolization for Treatment of Uveal Melanoma Hepatic Metastasis. Radiology. 2019 Oct;293(1):223-231. doi: 10.1148/radiol.2019190199.
14. Bethlehem MS, Katsarelias D, Olofsson Bagge R. Meta-Analysis of Isolated Hepatic Perfusion and Percutaneous Hepatic Perfusion as a Treatment for Uveal Melanoma Liver Metastases. Cancers (Basel). 2021;13(18):4726. DOI: 10.3390/cancers13184726.
15. Reddy SK, Kesmodel SB, Alexander HR Jr. Isolated hepatic perfusion for patients with liver metastases. Ther Adv Med Oncol. 2014;6(4):180-194. DOI: 10.1177/1758834014529175.
16. Olofsson R, Cahlin C, All-Ericsson C, et al. Isolated hepatic perfusion for ocular melanoma metastasis: registry data suggests a survival benefit. Ann Surg Oncol. 2014;21(2):466-472. DOI: 10.1245/s10434-013-3304-z.
17. Oldhafer KJ, Lang H, Frerker M, et al. First experience and technical aspects of isolated liver perfusion for extensive liver metastasis. Surgery. 1998;123(6):622-631.
18. Sigurdson ER, Ridge JA, Kemeny N, Daly JM. Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol. 1987;5(11):1836-1840. DOI: 10.1200/JCO.1987.5.11.1836.
19. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol. 1954;30(5):969-77.
20. Facy O, Doussot A, Zinzindohoué F, et al. Isolated hepatic perfusion: principles and results. J Visc Surg. 2014;151(Suppl 1):S25-32. DOI: 10.1016/j.jviscsurg.2013.12.006.
21. Shaji Mathew J, Kumar KYS, Nair K, et al. Antegrade Hepatic Artery and Portal Vein Perfusion Versus Portal Vein Perfusion Alone in Living Donor Liver Transplantation: A Randomized Trial. Liver Transpl. 2019;25(9):1353-1362. DOI: 10.1002/lt.25455.
22. Verhoef C, de Wilt JH, Brunstein F, et al. Isolated hypoxic hepatic perfusion with retrograde outflow in patients with irresectable liver metastases; a new simplified technique in isolated hepatic perfusion. Ann Surg Oncol. 2008 May;15(5):1367-74. doi: 10.1245/s10434-007-9714-z. Epub 2008 Feb 1. PMID: 18239976; PMCID: PMC2277449.
23. Rothbarth J, Pijl ME, Vahrmeijer AL, et al. Isolated hepatic, perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver. Br J Surg. 2003;90(11):1391-1397. DOI: 10.1002/bjs.4308.
24. van Iersel LB, Hoekman EJ, Gelderblom H, et al. Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases. Ann Surg Oncol. 2008;15(7):1891-1898. DOI: 10.1245/s10434-008-9881-6.
25. van Iersel LB, Verlaan MR, Vahrmeijer AL, et al. Hepatic artery infusion of high-dose melphalan at reduced flow during isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: a clinical and pharmacologic evaluation. Eur J Surg Oncol. 2007;33(7):874-881. DOI: 10.1016/j.ejso.2007.02.022.
26. van Iersel LBJ., Hoekman E J, Gelderblom H, et al,. Isolated Hepatic Perfusion with 200 mg Melphalan for Advanced Noncolorectal Liver Metastases. Annals of Surgical Oncology, 15(7), 1891–1898. doi:10.1245/s10434-008-9881-6
27. Rothbarth J, Tollenaar RA, Schellens JH, et al. Isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: recent trends and perspectives. Eur J Cancer. 2004;40(12):1812-1824. DOI: 10.1016/j.ejca.2004.04.009.
28. Wang LQ, Persson BG, Stenram U, Bengmark S. Influence of portal branch ligation on the outcome of repeat dearterializations of an experimental liver tumor in the rat. J Surg Oncol. 1994 Apr;55(4):229-34. doi: 10.1002/jso.2930550406. PMID: 7512673.
29. Watanabe Y, Püschel GP, Gardemann A, Jungermann K. Presinusoidal and proximal intrasinusoidal confluence of hepatic artery and portal vein in rat liver: functional evidence by orthograde and retrograde bivascular perfusion. Hepatology. 1994 May;19(5):1198-207. PMID: 8175142.
30. Fu X, Sluka JP, Clendenon SG, et al. Modeling of xenobiotic transport and metabolism in virtual hepatic lobule models. PLoS One. 2018 Sep 13;13(9):e0198060. doi: 10.1371/journal.pone.0198060. PMID: 30212461; PMCID: PMC6136710.
31. Rothbarth J, Sparidans RW, Beijnen JH, et al. Reduced liver uptake of arterially infused melphalan during retrograde rat liver perfusion with unaffected liver tumor uptake. J Pharmacol Exp Ther. 2002;303(2):736-740. DOI: 10.1124/jpet.102.037895.
32. van Etten B, de Wilt JH, Brunstein F, et al. Isolated hypoxic hepatic perfusion with melphalan in patients with irresectable ocular melanoma metastases. Eur J Surg Oncol. 2009 May;35(5):539-45. doi: 10.1016/j.ejso.2008.07.004. Epub 2008 Aug 28. PMID: 18760560.
33. Verhoef C, de Wilt JH, Brunstein F, et al. Isolated hypoxic hepatic perfusion with retrograde outflow in patients with irresectable liver metastases; a new simplified technique in isolated hepatic perfusion. Ann Surg Oncol. 2008;15(5):1367-1374. DOI: 10.1245/s10434-007-9714-z.
34. Karydis I, Gangi A, Wheater MJ, et al. Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease. J Surg Oncol. 2018;117(6):1170-1178. doi: 10.1002/jso.24956.
35. Artzner C, Mossakowski O, Hefferman G, et al. Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience. Cancer Imaging. 2019;19(1):31. doi: 10.1186/s40644-019-0218-4.
36. Vogl TJ, Koch SA, Lotz G, et al. Percutaneous Isolated Hepatic Perfusion as a Treatment for Isolated Hepatic Metastases of Uveal Melanoma: Patient Outcome and Safety in a Multi-centre Study. Cardiovasc Intervent Radiol. 2017;40(6):864-872. doi: 10.1007/s00270-017-1588-2.
Supplementary files
Review
For citations:
Unguryan V.M., Kazantsev A.N., Belov Y.V. Vascular access for isolated hepatic perfusion in liver metastases. Place of artificial circulation. Literature review. Russian Journal of Cardiology. 2023;28(6):5393. (In Russ.) https://doi.org/10.15829/1560-4071-2023-5393. EDN: YADTSI
Views:
743
Email this article 